중동 및 아프리카 박테리오파지 치료 시장, 대상(대장균, 포도상구균, 연쇄상구균, 녹농균, 살모넬라균, 기타), 유형(용해성, 용원성), 기반(멸균 배지 배양, 수용성 젤리 기반), 응용 분야(세균성 이질, 피부 및 비강 점막 감염, 화농성 피부 감염, 폐 및 흉막 감염, 수술 후 상처 감염, 기타), 투여 경로(경구, 비경구, 직장, 피부, 기타), 최종 사용자(병원, 전문 클리닉, 학술 연구 및 기관, 기타), 유통 채널(직접 입찰, 제3자 유통업체), 국가(사우디 아라비아, 남아프리카 공화국, UAE, 이스라엘, 쿠웨이트, 이집트 및 기타 중동 및 아프리카 국가) - 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 중동 및 아프리카 박테리오파지 치료 시장
중동 및 아프리카 박테리오파지 치료 시장은 2021년부터 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년부터 2028년까지의 예측 기간 동안 4.1%의 CAGR로 성장하고 있으며 2028년까지 107만 달러에 도달할 것으로 예상된다고 분석합니다.
박테리오파지는 파지 또는 박테리아 바이러스라고도 하며, 박테리아를 감염시키고 박테리아 감염을 치료하는 데 사용되는 바이러스 그룹 중 하나입니다. 박테리아가 내성을 개발할 때 항생제의 대안으로 사용될 수 있습니다. 박테리오파지는 항생제보다 훨씬 더 구체적입니다. 일반적으로 숙주 유기체뿐만 아니라 장내 미생물과 같은 다른 유익한 박테리아에도 무해하여 기회 감염 가능성을 줄입니다. 항생제 내성 감염의 유병률 증가와 연구 개발 활동 증가는 예측 기간 동안 시장 수요를 촉진한 주요 원동력입니다. 그러나 치료와 관련된 높은 비용과 숙련된 전문가의 부족은 예측 기간 동안 시장 성장을 제한할 것으로 예상되는 요인입니다.
새로운 파이프라인 약물의 존재, 시장 참여자의 전략적 이니셔티브, 의료 부문의 지출 증가는 중동 및 아프리카 박테리오파지 치료 시장에 수익성 있는 성장 기회를 제공할 것으로 예상됩니다. 그러나 박테리오파지 치료의 한계와 적절한 규제 지침의 부족은 중동 및 아프리카 박테리오파지 치료 시장 성장에 큰 과제로 작용합니다.
박테리오파지 요법 시장 보고서는 시장 점유율, 새로운 개발 및 제품 파이프라인 분석, 국내 및 지역 시장 참여자의 영향, 새로운 수익 주머니, 시장 규정의 변화, 제품 승인, 전략적 의사 결정, 제품 출시, 지리적 확장 및 시장의 기술 혁신 측면에서의 분석 기회에 대한 세부 정보를 제공합니다. 분석 및 시장 시나리오를 이해하려면 당사에 문의하여 분석가 브리핑을 받으세요. 당사 팀은 원하는 목표를 달성하기 위한 수익 영향 솔루션을 만드는 데 도움을 드립니다.
Middle East And Africa Bacteriophages Therapy Market Scope and Market Size
The bacteriophages therapy market is segmented on the basis of target, type, base, application, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of target, the Middle East and Africa bacteriophages therapy market is segmented into Escherichia coli, staphylococcus, streptococcus, pseudomonas, salmonella, others. In 2021 staphylococcus segment is expected to dominate the market owing to the increasing focus of manufacturers on the development of advanced drugs in this class.
- On the basis of type, the Middle East and Africa bacteriophages therapy market is segmented into lytic and lysogenic. In 2021, the lytic segment is expected to dominate the market because of abundance in nature and minor side effects.
- On the basis of the base, the Middle East and Africa bacteriophages therapy market is segmented into sterile broth culture, water-soluble jelly base. In 2021, sterile broth culture is expected to dominate the market as the bacteriophage is cultured at varying oxygen levels in sterile broth, and more specificity towards the bacteriophages is provided in broth culture.
- On the basis of application, the Middle East and Africa bacteriophages therapy market is segmented into bacterial dysentery, infections of the skin and nasal mucosa, suppurative skin infection, lung and pleural infections, post-operative wound infections, others. In 2021, the post-operative wound segment is expected to dominate the market due to the growing healthcare infrastructure globally, burgeoning population, and rapid technological advancements.
- On the basis of route of administration, the Middle East and Africa bacteriophages therapy market is segmented into oral, parenteral, rectal, dermal, others. In 2021, the oral segment is expected to dominate the market due to painless self -administration, and absorption in the whole length of GI.
- On the basis of end-user, the Middle East and Africa bacteriophages therapy market is segmented into hospitals, specialty clinics, academic research and institutes, others. In 2021, the hospital’s segment is expected to dominate the market due to safety and continuous care, along with patient empowerment.
- On the basis of distribution channels, the Middle East and Africa bacteriophages therapy market is segmented into direct sales and third-party distributors. In 2021, the direct tender segment is expected to dominate the market due to stronger customer orientation towards internal users and direct communication with suppliers.
Bacteriophages Therapy Market Country Level Analysis
The bacteriophages therapy market is analyzed, and market size information is provided on the basis of target, type, base, application, route of administration, end-user, and distribution channels.
The countries covered in the bacteriophages therapy market report are Saudi Arabia, South Africa, UAE, Israel, Kuwait, Egypt, the rest of the Middle East and Africa.
The direct tender segment in the Middle East & Africa region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of stronger customer orientation towards internal users and direct communication with suppliers. South Africa is expected to dominate the bacteriophage therapy market in the Middle East and Africa due to the rise in patient population and interest of key players in expanding their market presence in the middle east & Africa.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Increasing Private Sector Funding And Technological Advancements Are Boosting The Market Growth Of Bacteriophages Therapy.
The bacteriophages therapy market also provides you with detailed market analysis for every country’s growth in the bacteriophage therapy industry with drugs sales, the impact of advancement, technology, and changes in regulatory scenarios with their support for the OCD drugs market. The data is available for the historical period 2011 to 2019.
Competitive Landscape and Bacteriophages Therapy Market Share Analysis
Bacteriophages therapy market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus related to the bacteriophages therapy market.
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player is enhancing the company market in the bacteriophage therapy market, which also provides the benefit for the organization to improve their offering for bacteriophage therapy.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 TAREGET LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 MARKET APPLICATION COVERAGE GRID
2.11 VENDOR SHARE ANALYSIS
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PORTERS FIVE FORCES MODEL
4.2 PESTEL ANALYSIS
5 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: REGULATIONS
5.1 THE U.S. REGULATORY GUIDELINES FOR BACTERIOPHAGES
5.2 EUROPE REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.3 JAPAN REGULATORY GUIDELINE FOR BACTERIOPHAGE
5.4 AUSTRALIA REGULATORY GUIDELINE FOR BACTERIOPHAGE
6 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: REGIONAL SUMMARY
7 RESEARCH AND DEVELOPMENT ANALYSIS: MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET
7.1 PIPELINE ANALYSIS
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 INCREASING PREVALENCE OF ANTIBIOTIC-RESISTANT INFECTIONS
8.1.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
8.1.3 INCREASING GOVERNMENT FUNDING
8.1.4 INCREASING PRIVATE SECTOR FUNDING
8.1.5 TECHNOLOGICAL ADVANCEMENTS
8.2 RESTRAINTS
8.2.1 HIGH COST ASSOCIATED WITH BACTERIOPHAGE THERAPY
8.2.2 LACK OF SKILLED PROFESSIONALS
8.2.3 SIDE-EFFECTS OF BACTERIOPHAGE THERAPY
8.2.4 AVAILABILITY OF ALTERNATIVE THERAPIES FOR ANTIBIOTIC RESISTANCE
8.3 OPPORTUNITIES
8.3.1 PRESENCE OF NOVEL PIPELINE DRUGS
8.3.2 STRATEGIC INITIATIVES BY MARKET PLAYERS
8.3.3 INCREASING HEALTHCARE EXPENDITURE
8.4 CHALLENGES
8.4.1 LIMITATIONS OF BACTERIOPHAGE THERAPY
8.4.2 LACK OF PROPER REGULATORY GUIDELINES
9 IMPACT OF COVID-19 ON MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET
9.1 IMPACT ON THE PRICE
9.2 IMPACT ON DEMAND
9.3 IMPACT ON SUPPLY
9.4 STRATEGIC INITIATIVES BY MANUFACTURERS
9.5 CONCLUSION
10 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET
10.1 OVERVIEW
10.2 STAPHYLOCOCCUS
10.3 ESCHERICHIA COLI
10.4 PSEUDOMONAS
10.5 STREPTOCOCCUS
10.6 SALMONELLA
10.7 OTHERS
11 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE
11.1 OVERVIEW
11.2 LYTIC
11.3 LYSOGENIC
12 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE
12.1 OVERVIEW
12.2 STERILE BROTH CULTURE
12.3 WATER-SOLUBLE JELLY BASE
13 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION
13.1 OVERVIEW
13.2 POSTOPERATIVE WOUND INFECTIONS
13.3 INFECTIONS OF SKIN AND NASAL MUCOSA
13.4 BACTERIAL DYSENTERY
13.5 SUPPURATIVE SKIN INFECTIONS
13.6 LUNG AND PLEURAL INFECTION
13.7 OTHERS
14 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 LIQUID
14.2.2 TABLET
14.3 DERMAL
14.4 PARENTERAL
14.4.1 INTRAVENOUSLY
14.4.2 INTRAPLEURAL INJECTIONS
14.5 OTHERS
15 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 SPECILAITY CLINICS
15.4 ACADEMIC RESEARCH & INSTITUTES
15.5 OTHERS
16 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 DIRECT TENDER
16.3 THIRD PARTY DISTRIBUTORS
17 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY REGION
17.1 MIDDLE EAST & AFRICA
17.1.1 SOUTH AFRICA
17.1.2 SAUDI ARABIA
17.1.3 ISRAEL
17.1.4 EGYPT
17.1.5 REST OF MIDDLE EAST & AFRICA
18 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA
19 SWOT ANALYSIS
20 COMPANY PROFILE
20.1 MICROGEN
20.1.1 COMPANY SNAPSHOT
20.1.2 COMPANY SHARE ANALYSIS
20.1.3 PRODUCT PORTFOLIO
20.1.4 RECENT DEVELOPMENTS
20.2 ADAPTIVE PHAGE THERAPEUTICS
20.2.1 COMPANY SNAPSHOT
20.2.2 COMPANY SHARE ANALYSIS
20.2.3 PRODUCT PORTFOLIO
20.2.4 RECENT DEVELOPMENTS
20.3 PHAGELUX,INC
20.3.1 COMPANY SNAPSHOT
20.3.2 COMPANY SHARE ANALYSIS
20.3.3 PRODUCT PORTFOLIO
20.3.4 RECENT DEVELOPMENTS
20.4 LOCUS BIOSCIENCES, INC.
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ATCC
20.5.1 COMPANY SNAPSHOT
20.5.2 COMPANY SHARE ANALYSIS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 INTRALYTIX, INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 PRODUCT PORTFOLIO
20.6.3 RECENT DEVELOPMENTS
20.7 MICREOS
20.7.1 COMPANY SNAPSHOT
20.7.2 PRODUCT PORTFOLIO
20.7.3 RECENT DEVELOPMENT
20.8 PYLUM
20.8.1 COMPANY SNAPSHOT
20.8.2 TECHNOLOGY PORTFOLIO
20.8.3 RECENT DEVELOPMENTS
20.9 FIXED-PHAGE LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 PRODUCT PORTFOLIO
20.9.3 RECENT DEVELOPMENTS
20.1 ARMATA PHARMACEUTICALS, INC.
20.10.1 COMPANY SNAPSHOT
20.10.2 PRODUCT PORTFOLIO
20.10.3 RECENT DEVELOPMENTS
20.11 ARTHUR ANDREW MEDICAL
20.11.1 COMPANY SNAPSHOT
20.11.2 PRODUCT PORTFOLIO
20.11.3 RECENT DEVELOPMENT
20.12 CYTOPHAGE TECHNOLOGIES INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 PRODUCT PORTFOLIO
20.12.3 RECENT DEVELOPMENT
20.13 ENBIOTIX, INC.
20.13.1 COMPANY SNAPSHOT
20.13.2 PRODUCT PORTFOLIO
20.13.3 RECENT DEVELOPMENTS
20.14 INTODEWORLD, INC.
20.14.1 COMPANY SNAPSHOT
20.14.2 PRODUCT PORTFOLIO
20.14.3 RECENT DEVELOPMENT
20.15 NEXTBIOTICS
20.15.1 COMPANY SNAPSHOT
20.15.2 TECHNOLOGY PORTFOLIO
20.15.3 RECENT DEVELOPMENT
20.16 PHERECYDES PHARMA
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENT
21 QUESTIONNAIRE
22 RELATED REPORTS
표 목록
TABLE 1 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 2 MIDDLE EAST & AFRICA STAPHYLOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST & AFRICA ESCHERICHIA COLI IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST & AFRICA PSEUDOMONAS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST & AFRICA STREPTOCOCCUS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST & AFRICA SALMONELLA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST & AFRICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST & AFRICA LYTIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST & AFRICA LYSOGENIC IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST & AFRICA STERILE BROTH CULTURE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST & AFRICA WATER-SOLUBLE JELLY BASE IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST & AFRICA POSTOPERATIVE WOUND INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST & AFRICA INFECTIONS OF SKIN AND NASAL MUCOSA IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST & AFRICA BACTERIAL DYSENTERY IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST & AFRICA SUPPURATIVE SKIN INFECTIONS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST & AFRICA LUNG AND PLEURAL INFECTION IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST & AFRICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST & AFRICA DERMAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST & AFRICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST & AFRICA HOSPITALS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST & AFRICA SPECILIATY CLINICS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST & AFRICA ACADEMIC RESEARCH & INSTITUTES IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST & AFRICA OTHERS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST & AFRICA DIRECT TENDER IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST & AFRICA THIRD PARTY DISTRIBUTORS IN BACTERIOPHAGES THERAPY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST & AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 46 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 47 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 49 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 50 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 51 SOUTH AFRICA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 52 SOUTH AFRICA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 53 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 54 SOUTH AFRICA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 55 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 56 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 58 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 59 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 60 SAUDI ARABIA ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 SAUDI ARABIA PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 62 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 SAUDI ARABIA BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 65 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 66 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 67 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 68 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 69 ISRAEL ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 70 ISRAEL PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 71 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 72 ISRAEL BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 73 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
TABLE 74 EGYPT BACTERIOPHAGES THERAPY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 EGYPT BACTERIOPHAGES THERAPY MARKET, BY BASE, 2019-2028 (USD MILLION)
TABLE 76 EGYPT BACTERIOPHAGES THERAPY MARKET, BY APPLICATION, 2019-2028 (USD MILLION)
TABLE 77 EGYPT BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 78 EGYPT ORAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 79 EGYPT PARENTERAL IN BACTERIOPHAGES THERAPY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 80 EGYPT BACTERIOPHAGES THERAPY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 81 EGYPT BACTERIOPHAGES THERAPY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 82 REST OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET, BY TARGET, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET : MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET : COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: DBMR MARKET POSITION GRID
FIGURE 8 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 9 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SEGMENTATION
FIGURE 11 RISING INCIDENCE OF ANTIBIOTIC-RESISTANT INFECTIONS AND TECHNOLOGICAL ADVANCEMENTS ARE EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 12 STAPHYLOCOCCUS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET IN 2021 & 2028
FIGURE 13 NORTH AMERICA IS EXPECTED TO DOMINATE THE MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET AND ASIA-PACIFIC IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET
FIGURE 15 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2020
FIGURE 16 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, 2021-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET, LIFELINE CURVE
FIGURE 19 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2020
FIGURE 20 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, 2021-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2020
FIGURE 24 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, 2021-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY BASE, LIFELINE CURVE
FIGURE 27 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2020
FIGURE 28 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, 2021-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY APPLICATION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2020
FIGURE 36 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: SNAPSHOT (2020)
FIGURE 44 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020)
FIGURE 45 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: BY TARGET (2021-2028)
FIGURE 48 MIDDLE EAST & AFRICA BACTERIOPHAGES THERAPY MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.
